FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3138813244> ?p ?o ?g. }

• W3138813244 endingPage "S135" @default.
• W3138813244 startingPage "S135" @default.
• W3138813244 abstract "PurposeAssess the impact of tacrolimus-sirolimus (TAC/SRL) concentration on infection rate in heart transplant recipients (HTR).MethodsA retrospective review of HTR on TAC/SRL for > 1 year from 01/2006-08/2019 was conducted. Drug concentrations were defined as high (≥ 15 ng/mL) or low (<15 ng/mL), calculated as the summation of individual medication's annual average concentration for every year of therapy. The primary outcome was median rate of infection per year, defined as positive culture or other documented clinical finding treated with a course of antimicrobial. Secondary outcomes included incidence of infection, biopsy-proven acute rejection (BPAR), clinically evident cellular rejection treated with high-dose corticosteroids, and reason for SRL initiation and discontinuation.ResultsA total of 22 patients were included, 9 vs. 13 in the high and low TAC/SRL groups, respectively. Baseline characteristics were similar between groups. HTR in the high TAC/SRL group had higher median infection rate per year of therapy compared to those in the low group (1.67 vs 0.75, p<0.001). Numerically there were more patients with any cellular rejection (Grade 0R, 1R, 2R or 3R) in the high (100%) compared to the low group (77%). There were no cases of antibody mediated rejection in either group.ConclusionHigher combined concentrations of TAC/SRL in HTR resulted in increased infections per year. Due to the retrospective nature of this study, it is difficult to conclude the association between high TAC/SRL level and rejection severity. Given the small sample size and retrospective design, additional studies are warranted to confirm infection rates and to prospectively assess the association of high combined TAC/SRL concentrations on allograft rejection. Assess the impact of tacrolimus-sirolimus (TAC/SRL) concentration on infection rate in heart transplant recipients (HTR). A retrospective review of HTR on TAC/SRL for > 1 year from 01/2006-08/2019 was conducted. Drug concentrations were defined as high (≥ 15 ng/mL) or low (<15 ng/mL), calculated as the summation of individual medication's annual average concentration for every year of therapy. The primary outcome was median rate of infection per year, defined as positive culture or other documented clinical finding treated with a course of antimicrobial. Secondary outcomes included incidence of infection, biopsy-proven acute rejection (BPAR), clinically evident cellular rejection treated with high-dose corticosteroids, and reason for SRL initiation and discontinuation. A total of 22 patients were included, 9 vs. 13 in the high and low TAC/SRL groups, respectively. Baseline characteristics were similar between groups. HTR in the high TAC/SRL group had higher median infection rate per year of therapy compared to those in the low group (1.67 vs 0.75, p<0.001). Numerically there were more patients with any cellular rejection (Grade 0R, 1R, 2R or 3R) in the high (100%) compared to the low group (77%). There were no cases of antibody mediated rejection in either group. Higher combined concentrations of TAC/SRL in HTR resulted in increased infections per year. Due to the retrospective nature of this study, it is difficult to conclude the association between high TAC/SRL level and rejection severity. Given the small sample size and retrospective design, additional studies are warranted to confirm infection rates and to prospectively assess the association of high combined TAC/SRL concentrations on allograft rejection." @default.
• W3138813244 created "2021-03-29" @default.
• W3138813244 creator A5026585453 @default.
• W3138813244 creator A5035077372 @default.
• W3138813244 creator A5048777193 @default.
• W3138813244 creator A5055099464 @default.
• W3138813244 date "2021-04-01" @default.
• W3138813244 modified "2023-09-27" @default.
• W3138813244 title "Association of Infection Rate in Heart Transplant Recipients with Combined Tacrolimus and Sirolimus at High versus Low Concentration" @default.
• W3138813244 doi "https://doi.org/10.1016/j.healun.2021.01.420" @default.
• W3138813244 hasPublicationYear "2021" @default.
• W3138813244 type Work @default.
• W3138813244 sameAs 3138813244 @default.
• W3138813244 citedByCount "0" @default.
• W3138813244 crossrefType "journal-article" @default.
• W3138813244 hasAuthorship W3138813244A5026585453 @default.
• W3138813244 hasAuthorship W3138813244A5035077372 @default.
• W3138813244 hasAuthorship W3138813244A5048777193 @default.
• W3138813244 hasAuthorship W3138813244A5055099464 @default.
• W3138813244 hasBestOaLocation W31388132441 @default.
• W3138813244 hasConcept C120665830 @default.
• W3138813244 hasConcept C121332964 @default.
• W3138813244 hasConcept C126322002 @default.
• W3138813244 hasConcept C126894567 @default.
• W3138813244 hasConcept C141071460 @default.
• W3138813244 hasConcept C167135981 @default.
• W3138813244 hasConcept C2777921159 @default.
• W3138813244 hasConcept C2778715236 @default.
• W3138813244 hasConcept C2778849806 @default.
• W3138813244 hasConcept C2909675724 @default.
• W3138813244 hasConcept C2911091166 @default.
• W3138813244 hasConcept C61511704 @default.
• W3138813244 hasConcept C71924100 @default.
• W3138813244 hasConcept C90924648 @default.
• W3138813244 hasConceptScore W3138813244C120665830 @default.
• W3138813244 hasConceptScore W3138813244C121332964 @default.
• W3138813244 hasConceptScore W3138813244C126322002 @default.
• W3138813244 hasConceptScore W3138813244C126894567 @default.
• W3138813244 hasConceptScore W3138813244C141071460 @default.
• W3138813244 hasConceptScore W3138813244C167135981 @default.
• W3138813244 hasConceptScore W3138813244C2777921159 @default.
• W3138813244 hasConceptScore W3138813244C2778715236 @default.
• W3138813244 hasConceptScore W3138813244C2778849806 @default.
• W3138813244 hasConceptScore W3138813244C2909675724 @default.
• W3138813244 hasConceptScore W3138813244C2911091166 @default.
• W3138813244 hasConceptScore W3138813244C61511704 @default.
• W3138813244 hasConceptScore W3138813244C71924100 @default.
• W3138813244 hasConceptScore W3138813244C90924648 @default.
• W3138813244 hasIssue "4" @default.
• W3138813244 hasLocation W31388132441 @default.
• W3138813244 hasOpenAccess W3138813244 @default.
• W3138813244 hasPrimaryLocation W31388132441 @default.
• W3138813244 hasRelatedWork W1970601178 @default.
• W3138813244 hasRelatedWork W2009735756 @default.
• W3138813244 hasRelatedWork W2050005512 @default.
• W3138813244 hasRelatedWork W2054320327 @default.
• W3138813244 hasRelatedWork W2054355000 @default.
• W3138813244 hasRelatedWork W2064152041 @default.
• W3138813244 hasRelatedWork W2087821141 @default.
• W3138813244 hasRelatedWork W2146159635 @default.
• W3138813244 hasRelatedWork W2322728343 @default.
• W3138813244 hasRelatedWork W2641056067 @default.
• W3138813244 hasVolume "40" @default.
• W3138813244 isParatext "false" @default.
• W3138813244 isRetracted "false" @default.
• W3138813244 magId "3138813244" @default.
• W3138813244 workType "article" @default.